Our finding that ACAT inhibition can additionally act directly to reduce HBV particle genesis and secreted HBsAg release gives it the unique potential to exert multiple complementary modes of action in the therapy of HBV and HBV-related HCC. This evidence concerns the gene ACAT1 and hepatocellular carcinoma.